Claritas Pharmaceuticals Inc

PINK:CLAZF USA Biotechnology
Market Cap
$3.66K
Market Cap Rank
#46730 Global
#14528 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$14.46
About

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.

Claritas Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2012: 0.76%

Claritas Pharmaceuticals Inc (CLAZF) has an Asset Resilience Ratio of 0.76% as of September 2012. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$355.81K
Cash + Short-term Investments
Total Assets
$46.69 Million
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2009)

This chart shows how Claritas Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Claritas Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $355.81K 0.76%
Total Liquid Assets $355.81K 0.76%

Asset Resilience Insights

  • Limited Liquidity: Claritas Pharmaceuticals Inc maintains only 0.76% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Claritas Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Claritas Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Claritas Pharmaceuticals Inc (2007–2009)

The table below shows the annual Asset Resilience Ratio data for Claritas Pharmaceuticals Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2009-12-31 9.81% $2.93 Million $29.86 Million -3.72pp
2007-12-31 13.53% $4.48 Million $33.13 Million --
pp = percentage points